Q32 Bio Statistics

Total Valuation

Q32 Bio has a market cap or net worth of $31.30 million. The enterprise value is -$35.67 million.

Market Cap	31.30M
Enterprise Value	-35.67M

Important Dates

The next estimated earnings date is Thursday, April 3, 2025, before market open.

Earnings Date	Apr 3, 2025
Ex-Dividend Date	n/a

Share Statistics

Q32 Bio has 12.18 million shares outstanding. The number of shares has increased by 548.42% in one year.

Current Share Class	12.18M
Shares Outstanding	12.18M
Shares Change (YoY)	+548.42%
Shares Change (QoQ)	+0.94%
Owned by Insiders (%)	0.62%
Owned by Institutions (%)	36.81%
Float	3.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	-2.14
Forward PS	n/a
PB Ratio	1.71
P/TBV Ratio	1.71
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.53, with a Debt / Equity ratio of 1.21.

Current Ratio	6.53
Quick Ratio	6.23
Debt / Equity	1.21
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-59.53

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-61.10%
Return on Invested Capital (ROIC)	-214.37%
Return on Capital Employed (ROCE)	-85.83%
Revenue Per Employee	n/a
Profits Per Employee	-$1.64M
Employee Count	37
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Q32 Bio has paid $1.88 million in taxes.

Income Tax	1.88M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -82.67% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-82.67%
50-Day Moving Average	4.09
200-Day Moving Average	26.89
Relative Strength Index (RSI)	27.14
Average Volume (20 Days)	259,267

Short Selling Information

The latest short interest is 1.34 million, so 10.98% of the outstanding shares have been sold short.

Short Interest	1.34M
Short Previous Month	1.34M
Short % of Shares Out	10.98%
Short % of Float	34.52%
Short Ratio (days to cover)	3.65

Income Statement

In the last 12 months, Q32 Bio had revenue of -$14.66 million and -$60.61 million in losses. Loss per share was -$5.76.

Revenue	-14.66M
Gross Profit	-60.60M
Operating Income	-77.39M
Pretax Income	-65.02M
Net Income	-60.61M
EBITDA	-76.89M
EBIT	-77.39M
Loss Per Share	-$5.76

Full Income Statement

Balance Sheet

The company has $89.08 million in cash and $22.10 million in debt, giving a net cash position of $66.97 million or $5.50 per share.

Cash & Cash Equivalents	89.08M
Total Debt	22.10M
Net Cash	66.97M
Net Cash Per Share	$5.50
Equity (Book Value)	18.30M
Book Value Per Share	1.51
Working Capital	79.52M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$67.00 million and capital expenditures -$73,000, giving a free cash flow of -$67.07 million.

Operating Cash Flow	-67.00M
Capital Expenditures	-73,000
Free Cash Flow	-67.07M
FCF Per Share	-$5.51

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	527.79%
Pretax Margin	400.58%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Q32 Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-548.42%
Shareholder Yield	-548.42%
Earnings Yield	-193.62%
FCF Yield	-214.27%

Analyst Forecast

The average price target for Q32 Bio is $24.14, which is 839.30% higher than the current price. The consensus rating is "Hold".

Price Target	$24.14
Price Target Difference	839.30%
Analyst Consensus	Hold
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Q32 Bio has an Altman Z-Score of -2.12 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.12
Piotroski F-Score	2